Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Necrotizing soft tissue infections

INTRODUCTION

Necrotizing soft tissue infections include necrotizing forms of cellulitis, myositis, and fasciitis. These infections are characterized clinically by fulminant tissue destruction, systemic signs of toxicity, and high mortality. Accurate diagnosis and appropriate treatment must include early surgical intervention and antibiotic therapy.

Several different names have been used to describe the various forms of necrotizing infections; this is related in part to naming based on clinical features rather than surgical or pathologic findings. It is important to consider the many different types of necrotizing infections described in the literature because these descriptions may provide clinical clues needed for prompt intervention and management. The lay press has referred to organisms that cause necrotizing soft tissue infections as "flesh-eating bacteria."

Issues related to necrotizing cellulitis, fasciitis, and myositis will be reviewed here. Pyomyositis and myonecrosis are discussed separately. (See "Clostridial myonecrosis" and "Pyomyositis".)

MICROBIOLOGY

Necrotizing soft tissue infections are comprised of two distinct bacteriologic entities: type I (polymicrobial infection) and type II (group A streptococcal [GAS] infection). There are also case reports of monomicrobial necrotizing soft tissue infections due to other organisms, including Haemophilus influenzae [1-3].

In type I infection, at least one anaerobic species (most commonly Bacteroides, Clostridium, or Peptostreptococcus) is isolated in combination with one or more facultative anaerobic streptococci (other than group A) and members of the Enterobacteriaceae (eg, E. coli, Enterobacter, Klebsiella, Proteus) (table 1) [4-6]. An obligate aerobe, such as P. aeruginosa, is only rarely a component of such a mixed infection. Necrotizing fasciitis of the head and neck is usually caused by mouth anaerobes, such as Fusobacteria, anaerobic streptococci, Bacteroides, and spirochetes. Fournier’s gangrene is caused by facultative organisms (E. coli, Klebsiella, enterococci), along with anaerobes (Bacteroides, Fusobacterium, Clostridium, anaerobic or microaerophilic streptococci) [7].

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Dec 11, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. McLellan E, Suvarna K, Townsend R. Fatal necrotizing fasciitis caused by Haemophilus influenzae serotype f. J Med Microbiol 2008; 57:249.
  2. Resman F, Svensjö T, Ünal C, et al. Necrotizing myositis and septic shock caused by Haemophilus influenzae type f in a previously healthy man diagnosed with an IgG3 and a mannose-binding lectin deficiency. Scand J Infect Dis 2011; 43:972.
  3. Stumvoll M, Fritsche A. Necrotizing fasciitis caused by unencapsulated Haemophilus influenzae. Clin Infect Dis 1997; 25:327.
  4. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007; 44:705.
  5. Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995; 33:2382.
  6. Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85-A:1454.
  7. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg 2000; 87:718.
  8. Hau V, Ho CO. Necrotising fasciitis caused by Vibrio vulnificus in the lower limb following exposure to seafood on the hand. Hong Kong Med J 2011; 17:335.
  9. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.
  10. Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 2007; 45:450.
  11. Chelsom J, Halstensen A, Haga T, Høiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344:1111.
  12. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.
  13. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29:1562.
  14. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103:18.
  15. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J Infect Dis 2006; 193:1685.
  16. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705.
  17. Hackett SP, Stevens DL. Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. J Infect Dis 1993; 168:232.
  18. Stevens DL, Bryant AE, Hackett SP, et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996; 173:619.
  19. Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21:977.
  20. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.
  21. Bouza E, Bernaldo de Quirós JC, Rodríguez Créixems M, Quintans A. Fulminant myonecrosis due to Streptococcus pyogenes in a previously healthy patient. Eur J Clin Microbiol Infect Dis 1988; 7:205.
  22. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003; 82:225.
  23. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45:853.
  24. Das DK, Baker MG, Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990 to 2006. J Infect 2011; 63:429.
  25. Kimura AC, Higa JI, Levin RM, et al. Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis 2004; 38:e87.
  26. McGuigan CC, Penrice GM, Gruer L, et al. Lethal outbreak of infection with Clostridium novyi type A and other spore-forming organisms in Scottish injecting drug users. J Med Microbiol 2002; 51:971.
  27. Hasham S, Matteucci P, Stanley PR, Hart NB. Necrotising fasciitis. BMJ 2005; 330:830.
  28. Eneli I, Davies HD. Epidemiology and outcome of necrotizing fasciitis in children: an active surveillance study of the Canadian Paediatric Surveillance Program. J Pediatr 2007; 151:79.
  29. Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. Clin Infect Dis 1996; 23:698.
  30. Beaudoin AL, Torso L, Richards K, et al. Invasive group A Streptococcus infections associated with liposuction surgery at outpatient facilities not subject to state or federal regulation. JAMA Intern Med 2014; 174:1136.
  31. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1:69.
  32. Adams EM, Gudmundsson S, Yocum DE, et al. Streptococcal myositis. Arch Intern Med 1985; 145:1020.
  33. Svane S. Peracute spontaneous streptococcal myositis. A report on 2 fatal cases with review of literature. Acta Chir Scand 1971; 137:155.
  34. Yoder EL, Mendez J, Khatib R. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev Infect Dis 1987; 9:382.
  35. Mac Laurin JP. Spontaneous streptococcal myositis associated with disseminated intravascular coagulopathy. J Am Osteopath Assoc 1977; 76:675.
  36. Jahnson L, Berggren L, Björsell-Ostling E, et al. Streptococcal myositis. Scand J Infect Dis 1992; 24:661.
  37. Schwartz MN, Pasternack MS. Cellulitis and subcutaneous tissue infections. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.1172.
  38. Gozal D, Ziser A, Shupak A, et al. Necrotizing fasciitis. Arch Surg 1986; 121:233.
  39. Mathieu D, Neviere R, Teillon C, et al. Cervical necrotizing fasciitis: clinical manifestations and management. Clin Infect Dis 1995; 21:51.
  40. Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am 1994; 74:1339.
  41. Stephens BJ, Lathrop JC, Rice WT, Gruenberg JC. Fournier's gangrene: historic (1764-1978) versus contemporary (1979-1988) differences in etiology and clinical importance. Am Surg 1993; 59:149.
  42. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267:3315.
  43. MACLENNAN JD. The histotoxic clostridial infections of man. Bacteriol Rev 1962; 26:177.
  44. Sudarsky LA, Laschinger JC, Coppa GF, Spencer FC. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg 1987; 206:661.
  45. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.
  46. El-Khani U, Nehme J, Darwish A, et al. Multifocal necrotising fasciitis: an overlooked entity? J Plast Reconstr Aesthet Surg 2012; 65:501.
  47. Petitpas F, Blancal JP, Mateo J, et al. Factors associated with the mediastinal spread of cervical necrotizing fasciitis. Ann Thorac Surg 2012; 93:234.
  48. Hejase MJ, Simonin JE, Bihrle R, Coogan CL. Genital Fournier's gangrene: experience with 38 patients. Urology 1996; 47:734.
  49. Hsieh WS, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Pediatrics 1999; 103:e53.
  50. Jamal N, Teach SJ. Necrotizing fasciitis. Pediatr Emerg Care 2011; 27:1195.
  51. Walls T, Williams G, Adams S, et al. Neonatal necrotising fasciitis following superficial skin infection with community-associated methicillin-resistant Staphylococcus aureus. J Paediatr Child Health 2011; 47:918.
  52. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269:390.
  53. Simonart T, Simonart JM, Derdelinckx I, et al. Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin Infect Dis 2001; 32:E9.
  54. Yaghoubian A, de Virgilio C, Dauphine C, et al. Use of admission serum lactate and sodium levels to predict mortality in necrotizing soft-tissue infections. Arch Surg 2007; 142:840.
  55. Butterworth SA, Murphy JJ. Necrotizing soft tissue infections--are they different in healthy vs immunocompromised children? J Pediatr Surg 2006; 41:935.
  56. Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004; 32:1535.
  57. Wilson MP, Schneir AB. A case of necrotizing fasciitis with a LRINEC score of zero: clinical suspicion should trump scoring systems. J Emerg Med 2013; 44:928.
  58. Holland MJ. Application of the Laboratory Risk Indicator in Necrotising Fasciitis (LRINEC) score to patients in a tropical tertiary referral centre. Anaesth Intensive Care 2009; 37:588.
  59. Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J 1997; 90:1065.
  60. Bakleh M, Wold LE, Mandrekar JN, et al. Correlation of histopathologic findings with clinical outcome in necrotizing fasciitis. Clin Infect Dis 2005; 40:410.
  61. Zacharias N, Velmahos GC, Salama A, et al. Diagnosis of necrotizing soft tissue infections by computed tomography. Arch Surg 2010; 145:452.
  62. Becker M, Zbären P, Hermans R, et al. Necrotizing fasciitis of the head and neck: role of CT in diagnosis and management. Radiology 1997; 202:471.
  63. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol 1998; 170:615.
  64. Thekkemuriyi DV, John SG, Pillai U. 'Krokodil'--a designer drug from across the Atlantic, with serious consequences. Am J Med 2014; 127:e1.
  65. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23.
  66. EAGLE H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389.
  67. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167:1401.
  68. Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents 1994; 4:297.
  69. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18:1096.
  70. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995; 20 Suppl 2:S154.
  71. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057.
  72. Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631.
  73. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800.
  74. Norrby-Teglund A, Muller MP, Mcgeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37:166.
  75. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333.
  76. Yong JM. Necrotising fasciitis. Lancet 1994; 343:1427.
  77. Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35:950.
  78. Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 2014; 59:358.
  79. Sablier F, Slaouti T, Drèze PA, et al. Nosocomial transmission of necrotising fasciitis. Lancet 2010; 375:1052.
  80. Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology 2004; 64:218.
  81. Anaya DA, McMahon K, Nathens AB, et al. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005; 140:151.
  82. Huang KF, Hung MH, Lin YS, et al. Independent predictors of mortality for necrotizing fasciitis: a retrospective analysis in a single institution. J Trauma 2011; 71:467.